How much does everolimus (Afinitor) need to be taken in a month? Reasonable medication cycle recommendations

Everolimus (Everolimus) is an oral mTOR inhibitor that is widely used to prevent organ transplant rejection and treat various tumors, including kidney cancer, breast cancer, and pancreatic neuroendocrine tumors. The specific dosage and frequency of administration need to be adjusted individually based on the indications, patient weight, renal function and liver function. Adult kidney transplant patients usually take it orally once a day, usually at a dose of 0.75mg to 1.5mg, once a day, in combination with other immunosuppressants; the dose for tumor treatment may be higher or adjusted according to the course of treatment.

Take common kidney transplant regimens as an example. If 1mgeverolimus is taken daily, the cumulative dose in one month (30 days) is about 30mg. In tumor treatment, the dose may range from 5mg to 10mg daily, depending on patient tolerance and blood drug concentration. Therefore, the cumulative dose in one month can range from 150mg to 300mg. Blood drug concentration should be measured regularly during medication to ensure drug efficacy while reducing the risk of side effects.

Everolimus is generally a long-term maintenance treatment drug, and it is not recommended to stop the drug at will. For transplant patients, treatment usually needs to be continued for months to years to prevent rejection; for cancer patients, the length of treatment needs to be evaluated based on efficacy and tolerability. Some clinical plans are to take the drug continuously for 3 months to 6 months, and then decide whether to continue or adjust the dose based on imaging and laboratory indicators.

During the use of everolimus, patients need to regularly monitor blood routine, liver and kidney function, blood sugar and blood lipids, and pay attention to adverse reactions such as oral ulcers, infection risks and rashes. If obvious side effects occur, the dose needs to be adjusted or the drug temporarily discontinued under the guidance of a doctor. In addition, simultaneous use with strong CYP3A4 inhibitors or inducers should be avoided to avoid affecting blood concentration and therapeutic effect. Standardized and individualized medication can maximize the efficacy of everolimus and ensure safety.

Reference materials:https://www.drugs.com/